Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial

Rugo, HS; Im, SA; Cardoso, F; Cortes, J; Curigliano, G; Musolino, A; Pegram, MD; Wright, GS; Saura, C; Escriva-de-Romani, S; De Laurentiis, M; Levy, C; Brown-Glaberman, U; Ferrero, JM; de Boer, M; Kim, SB; Petrakova, K; Yardley, DA; Freedman, O; Jakobsen, EH; Kaufman, B; Yerushalmi, R; Fasching, PA; Nordstrom, JL; Bonvini, E; Koenig, S; Edlich, S; Hong, S; Rock, EP; Gradishar, WJ

Rugo, HS (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 1825 Fourth St,3rd Floor,POB 1710, San Francisco, CA 94158 USA.

JAMA ONCOLOGY, ; ():

Abstract

IMPORTANCE ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索